Suppression of presbyopia progression with pirenoxine eye drops: Experiments on rats and non-blinded, randomized clinical trial of efficacy

Yukari Tsuneyoshi, Akihiro Higuchi, Kazuno Negishi, Kazuo Tsubota

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.

Original languageEnglish
Article number6819
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Presbyopia
Ophthalmic Solutions
Lenses
Equipment and Supplies
Elasticity
Smoke
Cataract
Tobacco
Non-Randomized Controlled Trials
pirenoxine
Control Groups

ASJC Scopus subject areas

  • General

Cite this

Suppression of presbyopia progression with pirenoxine eye drops : Experiments on rats and non-blinded, randomized clinical trial of efficacy. / Tsuneyoshi, Yukari; Higuchi, Akihiro; Negishi, Kazuno; Tsubota, Kazuo.

In: Scientific Reports, Vol. 7, No. 1, 6819, 01.12.2017.

Research output: Contribution to journalArticle

@article{e12b79e378074920badf5257d561f321,
title = "Suppression of presbyopia progression with pirenoxine eye drops: Experiments on rats and non-blinded, randomized clinical trial of efficacy",
abstract = "Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.",
author = "Yukari Tsuneyoshi and Akihiro Higuchi and Kazuno Negishi and Kazuo Tsubota",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-07208-6",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Suppression of presbyopia progression with pirenoxine eye drops

T2 - Experiments on rats and non-blinded, randomized clinical trial of efficacy

AU - Tsuneyoshi, Yukari

AU - Higuchi, Akihiro

AU - Negishi, Kazuno

AU - Tsubota, Kazuo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.

AB - Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.

UR - http://www.scopus.com/inward/record.url?scp=85026469717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026469717&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-07208-6

DO - 10.1038/s41598-017-07208-6

M3 - Article

C2 - 28754903

AN - SCOPUS:85026469717

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 6819

ER -